International Flavors & Fragrances Inc.

Fundamentals5.0
Price Action5.0
News Sentiment6.0
AI Rating
5.0

Key Drivers

  • Strong gross margins
  • Positive free cashflow
  • High operating costs

AI
AI Summary

5.0

IFF's strategic pivot to higher‑margin Health & Biosciences makes IFF a conditional, multi‑year recovery play—require 3–6 quarters of consistent EBITDA beats, rising organic growth, or meaningful divestiture proceeds to justify holding, because the primary downside is large intangibles/amortization and execution risk on margin/ROIC improvement.

HnB
Amortization
Deleveraging‍

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

5.0

Key Financial Insights:

  • Strong gross margins
  • Positive free cashflow
  • High operating costs

IFF generates strong cash flow and gross margins but remains loss-making due to high operating costs and a large intangible asset base, leaving valuation elevated despite moderate leverage.

CashGeneration
HighCosts

Price Behavior

5.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Below MA
  • Sharp decline
  • Support $66–68

IFF is in a clear short-term downtrend—down ~17–18% over the last month, trading well below the ~$74.60 last-month moving average with near-term support around $66–68 and resistance near $81–82.

downtrend
rebound
Support Level: $66–68
Resistance Level: $81–82

Sharp ~17–18% drop from $80.91 to $66.62 over the last month

Sentiment & News

6.0

Key News Insights:

  • Portfolio divestiture
  • Latin America expansion
  • Investor sell‑downs

IFF is reshaping its portfolio while investing in Latin America and sustainable products amid shareholder sell‑downs and a regulatory probe, leaving shares under pressure despite analyst optimism.

Regulatory
Expansion

The mix of disposals, regional investment and regulatory scrutiny should pressure near‑term share sentiment but could stabilize if growth in Health & Biosciences offsets margin impacts